Stoke Therapeutics, Inc. STOK Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Stoke Therapeutics, Inc. (STOK) reported net unrealized gains (losses) on securities still held of -$658K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- Stoke Therapeutics, Inc.'s net unrealized gains (losses) on securities still held decreased by 1500.0% year-over-year, from $47K to -$658K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s net unrealized gains (losses) on securities still held?
- Over 3 years (2021 to 2025), Stoke Therapeutics, Inc.'s net unrealized gains (losses) on securities still held has grown at a 60.5% compound annual growth rate (CAGR), from -$168K to $694K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric represents the change in the fair value of available-for-sale securities held by the company that have not yet been sold. It reflects paper gains or losses resulting from market price fluctuations of the investment portfolio. Monitoring this helps investors understand the impact of market volatility on the company's balance sheet outside of core operating activities.